Wednesday, March 13, 2013

CTC Survey Results Released
Inbox
x

Andrew Kerry
3:08 AM (3 hours ago)

to me
  Dear MUTOMBO,







We recently ran a survey on Circulating Tumour Cells which questioned stakeholders
across drug development, academia, cancer hospitals and the technology sector on the
 challenges that they are facing in utilising CTCs in their research. 

I think you’ll find the results interesting:
  • 74.3% of respondents in the survey highlighted CTCs as either a "very high" or 
  • "high priority" for their organisation
  • When questioned what was the biggest challenges faced in this field the top 
  • challenge was identified as “Current technology is neither sensitive or specific 
  • enough” (33%) with the second biggest challenge being that “There is no agreed 
  • golden standard for technology” (25.5%)
  • A resounding 48.8% thought that to validate CTCs in the clinic there needs to be
  •  “more clinical trials validating CTCs as a diagnostic/prognostic prospective
These are just some of the revealing answers the survey uncovered. You can download
the full survey results from the World CTC Berlin Library.

In addition to these exciting results I’d also like to take the opportunity to announce the
latest speaker for World CTC Berlin:

Sarah Thayer, Associate Professor, Surgery, W. Gerald Austen Scholar in Academic
Surgery & Director, Pancreatic Biology Laboratory, Mass Gen Hospital

Presentation Title: The Capture, Growth and Genetic Analysis of CTC in PDAC: What
 Can it Tell Us About this Disease?
  • Detection of CTC in patients with resectable PDAC using a Screencells Device
  • Methods used to achieve in vitro growth and confirmation of tumorigenicity
  • How selective deep sequencing was used to demonstrate the feasibility of
  •  identifying mutations present in the primary tumour and their corresponding CTC
Download the meeting brochure to see the full array of CTC experts on the programme.

Kind regards

Andrew

Andrew Kerry
Hanson Wade

Post a Comment